Frontlight ResearchEarly access
Active, not recruitingNo phase
Gracie Diet for Gastroesophageal Reflux Disease
Key facts
- Who runs it
- Johns Hopkins University
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- People taking part
- 30 people, planned
- Started
- 13 Nov 2020
- Expected to end
- Dec 2027
- Type of study
- Interventional
- Treatments tested
- Gracie Diet
- Record updated
- 16 January 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Age 18 years or older at registration
- Patients with ongoing symptoms of GERD: heartburn (pyrosis) mid-sternal chest pain, regurgitation of fluid or food, development of esophageal inflammation that may lead to swallowing dysfunction, or extraesophageal manifestations (i.e. cough, bronchospasms, and hoarseness)
- Use of one of the following PPI medications: omeprazole, lansoprazole, pantoprazole, rabeprazole, esomeprazole or dexlansoprazole. And/or use of one of the following H2 blockers medications as well: famotidine, cimetidine, ranitidine or nizatidine
- Willing to comply with the Gracie diet regimen
Who cannot take part
- A prior surgery of the upper gastrointestinal tract
- Complicated oropharyngeal dysphagia or other condition with risk for aspiration from oral ingestion
- Exclusion of other causes of symptoms as mechanical gastrointestinal obstruction, Barrett's esophagus and cancer of the esophagus by standard radiographic or endoscopic test evidenced in the medical record chart
- Failure to give informed consent
- Any other condition, which in the opinion of the investigator would impede compliance or hinder the completion of the study
- Age < than 18 years
- Patients unable to speak English
- Pregnancy or nursing
Where in United States
- Johns Hopkins Bayview Medical CenterBaltimore, United States
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if dietary changes can help improve gastroesophageal reflux disease (GERD) symptoms. The main question[s] it aims to answer whether the Gracie Diet is an option to treat GERD symptoms in individuals wish to discontinue standard doses of PPI and / or H2 receptor antagonists.
Read full original descriptionShow less
Participants will be taken off PPI and be placed on the Gracie Diet for 8 weeks. Information about the participants reflux symptoms and GERD health related quality of life will be collected to assess the effect of the diet.
The group in the trial
- Gracie DietTreatment being tested
Patients will have a nutritional consultation and will follow the Gracie diet for a month.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 16 January 2026